Literature DB >> 17932107

A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism.

J H Duncan Bassett1, Allan J Williams, Elaine Murphy, Alan Boyde, Peter G T Howell, Rowan Swinhoe, Marta Archanco, Frédéric Flamant, Jacques Samarut, Sabine Costagliola, Gilbert Vassart, Roy E Weiss, Samuel Refetoff, Graham R Williams.   

Abstract

By proposing TSH as a key negative regulator of bone turnover, recent studies in TSH receptor (TSHR) null mice challenged the established view that skeletal responses to disruption of the hypothalamic-pituitary-thyroid axis result from altered thyroid hormone (T(3)) action in bone. Importantly, this hypothesis does not explain the increased risk of osteoporosis in Graves' disease patients, in which circulating TSHR-stimulating antibodies are pathognomonic. To determine the relative importance of T(3) and TSH in bone, we compared the skeletal phenotypes of two mouse models of congenital hypothyroidism in which the normal reciprocal relationship between thyroid hormones and TSH was intact or disrupted. Pax8 null (Pax8(-/-)) mice have a 1900-fold increase in TSH and a normal TSHR, whereas hyt/hyt mice have a 2300-fold elevation of TSH but a nonfunctional TSHR. We reasoned these mice must display opposing skeletal phenotypes if TSH has a major role in bone, whereas they would be similar if thyroid hormone actions predominate. Pax8(-/-) and hyt/hyt mice both displayed delayed ossification, reduced cortical bone, a trabecular bone remodeling defect, and reduced bone mineralization, thus indicating that the skeletal abnormalities of congenital hypothyroidism are independent of TSH. Treatment of primary osteoblasts and osteoclasts with TSH or a TSHR-stimulating antibody failed to induce a cAMP response. Furthermore, TSH did not affect the differentiation or function of osteoblasts or osteoclasts in vitro. These data indicate the hypothalamic-pituitary-thyroid axis regulates skeletal development via the actions of T(3).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932107      PMCID: PMC2234586          DOI: 10.1210/me.2007-0221

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  48 in total

1.  Expression of cyclin-dependent kinase inhibitors in epiphyseal chondrocytes induced to terminally differentiate with thyroid hormone.

Authors:  R T Ballock; X Zhou; L M Mink; D H Chen; B C Mita; M C Stewart
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

2.  Requirements for DXA for the management of osteoporosis in Europe.

Authors:  J A Kanis; O Johnell
Journal:  Osteoporos Int       Date:  2004-12-24       Impact factor: 4.507

3.  Catch-up growth after prolonged hypothyroidism.

Authors:  B Boersma; B J Otten; G B Stoelinga; J M Wit
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

Review 4.  Effects of thyroid hormones on bone and mineral metabolism.

Authors:  L Mosekilde; E F Eriksen; P Charles
Journal:  Endocrinol Metab Clin North Am       Date:  1990-03       Impact factor: 4.741

5.  Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.

Authors:  E S Park; H Kim; J M Suh; S J Park; S H You; H K Chung; K W Lee; O Y Kwon; B Y Cho; Y K Kim; H K Ro; J Chung; M Shong
Journal:  Mol Endocrinol       Date:  2000-05

6.  Thyroid function and effect of aging in combined hetero/homozygous mice deficient in thyroid hormone receptors alpha and beta genes.

Authors:  R E Weiss; O Chassande; E K Koo; P E Macchia; K Cua; J Samarut; S Refetoff; S Refetoff
Journal:  J Endocrinol       Date:  2002-01       Impact factor: 4.286

7.  Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland.

Authors:  Jae Mi Suh; Jung Hun Song; Dong Wook Kim; Ho Kim; Hyo Kyun Chung; Jung Hwan Hwang; Jin Man Kim; Eun Suk Hwang; Jongkyeong Chung; Jeung-Hwan Han; Bo Youn Cho; Heung Kyu Ro; Minho Shong
Journal:  J Biol Chem       Date:  2003-03-30       Impact factor: 5.157

8.  Congenital hypothyroid Pax8(-/-) mutant mice can be rescued by inactivating the TRalpha gene.

Authors:  Frédéric Flamant; Anne-Lise Poguet; Michelina Plateroti; Olivier Chassande; Karine Gauthier; Nathalie Streichenberger; Ahmed Mansouri; Jacques Samarut
Journal:  Mol Endocrinol       Date:  2002-01

9.  Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation.

Authors:  N F Ray; J K Chan; M Thamer; L J Melton
Journal:  J Bone Miner Res       Date:  1997-01       Impact factor: 6.741

10.  TSH-activated signaling pathways in thyroid tumorigenesis.

Authors:  Marcos Rivas; Pilar Santisteban
Journal:  Mol Cell Endocrinol       Date:  2003-12-31       Impact factor: 4.102

View more
  43 in total

Review 1.  Thyroid disease in pregnancy in 2011: Thyroid function--effects on mother and baby unraveled.

Authors:  Anthony P Weetman
Journal:  Nat Rev Endocrinol       Date:  2011-12-06       Impact factor: 43.330

Review 2.  Role and Mechanisms of Actions of Thyroid Hormone on the Skeletal Development.

Authors:  Ha-Young Kim; Subburaman Mohan
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

3.  Subclinical thyroid dysfunction and incident hip fracture in older adults.

Authors:  Jennifer S Lee; Petra Buzková; Howard A Fink; Joseph Vu; Laura Carbone; Zhao Chen; Jane Cauley; Doug C Bauer; Anne R Cappola; John Robbins
Journal:  Arch Intern Med       Date:  2010-11-22

Review 4.  The multiple faces of autoimmune-mediated bone loss.

Authors:  Georg Schett; Jean-Pierre David
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

5.  Subclinical Changes in Maternal Thyroid Function Parameters in Pregnancy and Fetal Growth.

Authors:  Lauren E Johns; Kelly K Ferguson; David E Cantonwine; Bhramar Mukherjee; John D Meeker; Thomas F McElrath
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

6.  The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.

Authors:  Risheng Ma; Syed Morshed; Rauf Latif; Mone Zaidi; Terry F Davies
Journal:  Thyroid       Date:  2011-07-11       Impact factor: 6.568

7.  Fetal thyroid hormone level at birth is associated with fetal growth.

Authors:  Beverley M Shields; Beatrice A Knight; Anita Hill; Andrew T Hattersley; Bijay Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2011-03-16       Impact factor: 5.958

8.  Bioceramic-collagen scaffolds loaded with human adipose-tissue derived stem cells for bone tissue engineering.

Authors:  Neda Daei-Farshbaf; Abdolreza Ardeshirylajimi; Ehsan Seyedjafari; Abbas Piryaei; Fatemeh Fadaei Fathabady; Mehdi Hedayati; Mohammad Salehi; Masoud Soleimani; Hamid Nazarian; Sadegh-Lotfalah Moradi; Mohsen Norouzian
Journal:  Mol Biol Rep       Date:  2013-12-21       Impact factor: 2.316

9.  Thyroid-stimulating hormone, thyroid hormones, and bone loss.

Authors:  Mone Zaidi; Terry F Davies; Alberta Zallone; Harry C Blair; Jameel Iqbal; Surinder S Moonga; Jeffrey Mechanick; Li Sun
Journal:  Curr Osteoporos Rep       Date:  2009-07       Impact factor: 5.096

10.  Iodothyronine deiodinase enzyme activities in bone.

Authors:  Allan J Williams; Helen Robson; Monique H A Kester; Johannes P T M van Leeuwen; Stephen M Shalet; Theo J Visser; Graham R Williams
Journal:  Bone       Date:  2008-04-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.